Christopher Mason
Directeur/Membre du Conseil chez KRYSTAL BIOTECH, INC.
Fortune : - $ au 30/06/2024
Profil
Christopher Mason was the founder of Avrobio, Inc. (founded in 2015) where he held the title of Chief Scientific Officer from 2015 to 2022.
He is also the founder of Oribiotech Ltd.
(founded in 2015) where he currently serves as a Non-Executive Director.
In addition, Dr. Mason is the founder of London Regenerative Medicine Network Ltd.
(founded in 2008) where he is currently a Director.
He also founded Stem Cell Translation Ltd.
(founded in 2006) where he served as a Director from 2006 to 2018.
Recently, Dr. Mason founded Sun Vectors, Inc. (founded in 2022) and currently holds the title of Chief Executive Officer & Director.
Dr. Mason's current jobs include being a Director at Alliance for Regenerative Medicine since 2021, an Independent Director at Krystal Biotech, Inc. since 2021, and a Professor at University College London since 1999.
His former jobs include being a Trustee at UK Stem Cell Foundation from 2010 to 2016 and a Trustee at The British Neurological Research Trust from 2012 to 2016.
Dr. Mason's education history includes an undergraduate degree from Imperial College London, a doctorate degree from University College London, and another doctorate degree from King's College London.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
KRYSTAL BIOTECH, INC.
-.--% | 30/06/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Christopher Mason
| Sociétés | Poste | Début |
|---|---|---|
| KRYSTAL BIOTECH, INC. | Directeur/Membre du Conseil | 04/01/2021 |
Oribiotech Ltd.
 Oribiotech Ltd. BiotechnologyHealth Technology Oribiotech Ltd. Engages in Cell and Gene Therapy (CGT) manufacturing. The company was founded by Farlan Veraitch and Chris Mason on September 2, 2015 and is headquartered in London, the United Kingdom. | Fondateur | 01/09/2015 |
| London Regenerative Medicine Network Ltd. | Fondateur | 01/02/2008 |
| University College London | Corporate Officer/Principal | - |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Directeur/Membre du Conseil | 01/10/2021 |
Anciens postes connus de Christopher Mason
| Sociétés | Poste | Fin |
|---|---|---|
| TECTONIC THERAPEUTIC, INC. | Fondateur | 30/06/2022 |
| Stem Cell Translation Ltd. | Fondateur | 01/03/2018 |
| The British Neurological Research Trust | Directeur/Membre du Conseil | 01/05/2016 |
| UK Stem Cell Foundation | Directeur/Membre du Conseil | 01/05/2016 |
Formation de Christopher Mason
| Imperial College London | Undergraduate Degree |
| University College London | Doctorate Degree |
| King's College London | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| KRYSTAL BIOTECH, INC. | Health Technology |
| Entreprise privées | 7 |
|---|---|
| UK Stem Cell Foundation | Miscellaneous |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
| The British Neurological Research Trust | |
Avrobio, Inc.
 Avrobio, Inc. BiotechnologyHealth Technology AVROBIO, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Watertown, MA. | Health Technology |
Oribiotech Ltd.
Oribiotech Ltd. BiotechnologyHealth Technology Oribiotech Ltd. Engages in Cell and Gene Therapy (CGT) manufacturing. The company was founded by Farlan Veraitch and Chris Mason on September 2, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
| London Regenerative Medicine Network Ltd. | |
| Stem Cell Translation Ltd. |
